

FOR IMMEDIATE RELEASE: 10/26/18

Next Science Group  
Level 19, Tower A, The Zenith  
821 Pacific Highway, Chatswood  
NSW 2067  
Australia

Next Science, LLC  
10550 Deerwood Park Blvd  
Suite 300  
Jacksonville, FL 32256  
USA

## Next Science® Xbio™ Technology Expands Use into the Operating Room

**Sydney, NSW and Jacksonville, FL:** Next Science® is excited to announce the release of its newest product, SurgX™, available in the US market. SurgX is an innovative and first of its type, sterile antimicrobial surgical wound gel designed to help reduce superficial surgical site infections (SSIs) through the management and protection of the post-surgical wound site that facilitates natural healing.

SSIs have been a prevalent and costly problem in the healthcare industry. According to the CDC, SSIs are among the most common healthcare associated infections (HAI) with hundreds of thousands of people affected each year. In the United States alone, SSIs are estimated to account for up to \$10 billion dollars in healthcare expenditures annually.<sup>1</sup>

SurgX™ leverages Next Science's proprietary Xbio™ technology in a comprehensive sterile gel. The clever combination of proven ingredients and elegant chemistry provides a moist wound environment while destroying pathogens within the gel and defends post-surgical wounds from infection causing bacteria and biofilm formation. The sterile gel creates a protective superhydrophilic layer that prevents surface attachment of free-floating bacteria while the Xbio technology eliminates pathogens in the gel.

"SurgX is able to be used in the OR sterile field and should be applied directly to the surgical site wound following closure." explains Next Science® CTO, Matthew Myntti Ph.D, "The Xbio technology within the gel prevents bacterial adhesion without maceration through the formation of an oxygen permeable superhydrophilic surface."

Tests confirm bacteria are unable to migrate through or proliferate within the presents of SurgX. The gel formulation quickly conforms to the wound-bed on and around the surgical site and maintains a consistent barrier that can defend against biofilm colonization for up to 72 hours.

1. Mu Y, Edwards JR. Improving Risk-Adjusted Measures of Surgical Site Infection for the National Healthcare Safety Network. *Infection Control and Hospital Epidemiology*. 2011; 32(10): 970-986

# NEXT SCIENCE®

For more information about our products available in the US, please message Next Science®, LLC at [sales@nextscience.com](mailto:sales@nextscience.com)

## **About the Next Science® Group**

Next Science® pioneers innovative, proprietary technologies to address the problem of bacterial biofilms. With proven, experienced management and scientific leadership, Next Science® and its partners deliver break-through solutions that see beyond the current limits imposed by powerful bacterial colonies. Learn more at [www.nextscience.com](http://www.nextscience.com)

###

## **Inquiries:**

### **Don Ayers**

Vice President, Sales & Marketing

+1 855-564-2762

[sales@nextscience.com](mailto:sales@nextscience.com)